Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRK6 | P43250 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166291 | 0.80 | KCNA5 (0.59) | PTGDR2KMT2ARXRARXRBHSD17B10 | |
| SCHEMBL4156618 | 0.78 | KMT2A (0.52) | KMT2AHSD17B10RECQLKDM4EUSP2 | |
| SCHEMBL6856938 | 0.76 | PTGDR2 (0.44) | PTGDR2RXRARXRBHSD17B10RECQL | |
| SCHEMBL4052629 | 0.76 | GAPDH (0.46) | KMT2AHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23703568 | 0.72 | HSD17B10 (0.41) | PTGDR2HSD17B10 | |
| SCHEMBL4207967 | 0.71 | PTGS1 (0.59) | THRATHRBUSP2VDRPPARD | |
| SCHEMBL473881 | 0.70 | HSD17B10 (0.63) | KMT2ATHRBHSD17B10RECQLKDM4E | |
| SCHEMBL4055913 | 0.70 | LMNA (0.46) | KMT2ARXRARXRBTHRATHRB | |
| SCHEMBL4405072 | 0.70 | CYP1A2 (0.53) | KMT2AHSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL4206771 | 0.70 | SLC13A5 (0.61) | RXRARXRBVDRPPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | PTGDR2 37/4885KMT2A 2400/4885RXRA 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.